Introduction
Phototoxicity has been found to occur in both laboratory animals and humans when exposed to sunlight (or UVA) following the administration of fluoroquinolones. 1, 2 In humans it may be noted as exaggerated sunburn, scaling and blisters, while in animal models, such as the mouse, it can be seen as erythema and oedema of the ears. The newer fluoroquinolones are generally more potent antimicrobial agents, with more desirable pharmacokinetic properties and improved activity, but there has also been an increase in the incidence and/or severity of phototoxicity caused by these drugs. Sparfloxacin, for example, was associated with a sharp rise in the number of spontaneous reports of photosensitivity (often with blisters) in France soon after approval in early 1995. Clinical trials outside the USA revealed an incidence of only 2%, although some indication of the potential risk was seen in US clinical trials where phototoxic reactions were seen at an incidence of 8%. 3 At the same time, studies in hairless mice showed that this class of drug may also have the potential to be co-carcinogenic when administered concurrently with ultraviolet light. 4 Strengthened precautionary measures have now been introduced into the prescribing information for fluoroquinolones to minimize exposure to direct sunlight or artificial ultraviolet light.
Grepafloxacin is a new, oral, once-daily fluoroquinolone with potent activity against community-acquired respiratory pathogens including Streptococcus pneumoniae. Grepafloxacin has been licensed to GlaxoWellcome by Otsuka Pharmaceutical Co. Ltd. This study was performed by Otsuka in order to compare the phototoxic potential of grepafloxacin with that of a number of marketed fluoroquinolones.
Materials and methods

Chemicals
The test materials were grepafloxacin, sparfloxacin, lomefloxacin, enoxacin, ciprofloxacin and ofloxacin. Grepafloxacin, sparfloxacin and lomefloxacin were provided by the Second Tokushima Factory, Otsuka Pharmaceutical Co. Ltd, while ciprofloxacin, ofloxacin and enoxacin were extracted from commercial tablets. All drugs were prepared as 2% (w/v) suspensions in a solution of 5% (w/v) gum arabic (Gokyo Industries, Tokyo, Japan) in distilled water (Otsuka Pharmaceutical Factory, Inc.). The control material was a solution of 5% (w/v) gum arabic in distilled water.
Study design
Groups of five female Balb/c mice (5-6 weeks of age; Charles River Japan, Inc., Kanagawa, Japan) received either control material or grepafloxacin, sparfloxacin, lomefloxacin, ofloxacin, ciprofloxacin or enoxacin at an oral dose of 200 mg/kg. Commencing 30 min after dosing, the animals were exposed to UVA light at an intensity of 20 J/cm 2 for 110-115 min according to a modified method of Wagai and co-workers. 5 The light source was a medical ultraviolet-ray irradiation lamp (Dermaray M-DMR-1; Toshiba Medical Instrument Co., Ltd, Tokyo, Japan) with a bank of ten Toshiba 'Black Light' tubes (peak output © 1998 The British Society for Antimicrobial Chemotherapy JAC photoactivation of fluoroquinolones to reactive species, 6 a 3 mm thick pane of glass was placed between the light source and the animals to filter out any short wavelengths ( 320 nm) (UVB). Additional groups, each of three females, received the same doses, but were not exposed to UVA light. All doses were administered by oral gavage (10 mL/kg) as this is a clinical route of administration for all of the quinolones, including grepafloxacin.
Clinical assessment
The general condition of all animals was recorded before dosing and 30 min and 24, 48, 72, 96, 120, 144, and 168 h after the completion of irradiation. The ears of the animals were evaluated for erythema, oedema and auricular thickness at the same timepoints. Erythema and oedema were scored for severity on a scale of 1 to 4 by visual inspection, according to a standard scoring system commonly used to assess responses to dermal injury. 7 Ear thickness was measured using a dial gauge (Peacock, Ozaki Co., Tokyo, Japan). The animals were weighed on the day of dosing, and 3 and 7 days later.
Results
Phototoxic reactions of the ears were absent from all control animals regardless of whether they had been exposed to UVA irradiation or not. None of the quinolones caused effects in the absence of UVA light, but erythema of the ears was associated with administration of all of the quinolones following exposure to UVA light. Lomefloxacin and sparfloxacin caused erythema and oedema which were often severe and lasted the full 7 days of the study. Enoxacin caused a long-lasting erythema, while the erythema seen following the administration of grepafloxacin, ciprofloxacin and ofloxacin was relatively mild and short-lived (Figure 1) .
Measurement of auricular thickness gave results similar to those from the scoring of oedema of the ears. Lomefloxacin and sparfloxacin again caused severe effects (Figure 2) , with no changes being seen for grepafloxacin-, enoxacin-, ciprofloxacin-or ofloxacin-treated animals. For lomefloxacin-treated animals, auricular thickness was increased for all animals from 24 h after completion of irradiation; the increase was greatest at 120 h and decreased thereafter, but the ears were still swollen at the end of the 168 h observation period. Similar, but less severe, changes were seen for the sparfloxacin group.
Alopecia was noted 144 and 168 h after the completion of irradiation in three animals which had received lomefloxacin at 200 mg/kg, and were subsequently exposed to UVA. No other clinical observations related to treatment were seen and there were no treatment-related body weight changes following administration of any of the quinolones.
Discussion
Fluoroquinolone phototoxicity has, in the past, been estimated by measuring rates of degradation of the parent compound and by measuring cellular damage in vitro. 4 However, in-vivo models are preferred for the prediction of phototoxicity in humans as they incorporate the photoreactivity of the material, half-life, metabolism, whole animal distribution (including skin penetration) and toxicity to the skin. The in-vivo mouse model of Wagai and co-workers 5 has been used by a number of investigators to test the phototoxic potential of quinolones as it allows administration via the clinical route and precise control of the intensity and duration of ultraviolet light irradiation. It also makes use of clinically relevant and highly sensitive quantitative endpoints. Most importantly, there does appear to be a good correlation of such mouse models with regard to relative phototoxicity in humans. 8 Investigation of structure-activity relationships has led to the belief that the constituent at the X 8 position of a fluoroquinolone is mainly responsible for phototoxic potential, those with a halogen having the highest potential (for example lomefloxacin and sparfloxacin), while substitution with a methoxy group effectively reduces phototoxicity. Domagala 8 lists the potential for phototoxicity in the order (CF CCl N CH CF 3 ). Obviously quinolones which reach high concentrations or accumulate in skin have the potential to induce phototoxic reactions in this tissue. Accumulation in the skin is usually facilitated by a bulky side-chain or a methyl group at the R 5 position; the presence of such a constituent would give a lower no-effect dose than predicted by the X 8 group alone. Grepafloxacin has a CH at the X 8 position and a CH 3 at the R 5 position, so it would be expected to have a relatively low potential for phototoxicity, but to reach high concentrations or to accumulate in the skin. The results from this study suggest that grepafloxacin does have a low risk for phototoxicity, comparable to that of ciprofloxacin and ofloxacin, which are acknowledged to be two of the least phototoxic fluoroquinolones in experimental animals and humans. 4, 8 The results for lomefloxacin and sparfloxacin correlate with findings in humans where high incidences of phototoxicity (of up to 10 and 8%, respectively) have been reported. 3, 4 In human volunteers, grepafloxacin has been found to be a weak photosensitizer, equivalent to ciprofloxacin. 9 Results from extensive clinical trials also indicate a low potential of grepafloxacin for photosensitivity with reactions being noted at an incidence of 1.5%. This is a low incidence considering that no advice to avoid exposure to sunlight or UVA was given to patients. Therefore, although all quinolones have been reported to cause phototoxicity, grepafloxacin appears to be one of the least potent in preclinical studies; this has been confirmed in patients. 
